Clinical Trial Registration Number for SURMOUNT-2 NCT04657003
The STEP 1 trial extension the largest semaglutide follow-up study found that participants regained roughly two-thirds of their prior weight loss within 52 weeks of stopping the drug
British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, and Atlantic provinces generally cover GLP-1 medications only for diabetes indications
The cost savings associated with generic medications can lead to improved adherence and better health outcomes, as more patients can afford the treatment they need without the financial burden of high out-of-pocket expenses
The Microdose GLP-1 Protocol ($129/month flat) may suit patients sensitive to standard strengths
At least four other trials focused on weight-loss drugs have found the same rebound effect after quitting, including one trial focused on semaglutide (Wegovy)